Compare Cognizant Technology Solutions Corp (CTSH) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Revvity Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.2 (market cap $27.03B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Cognizant Technology Solutions Corp is the larger of the two by market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.2%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Revvity Inc for 12 Days on average.
| CTSH | RVTY | |
|---|---|---|
Market Cap | $27.03B | $16.98B |
Volume | 9,883,888 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $86.70 | $157.36 |
52-Week Low | $38.73 | $82.26 |
Typical Hold Time | 57 Days | 12 Days |
Enterprise Value | $28.08B | $19.30B |
Dividend Yield | 2.2% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $60.01, up 5.15% over 24 hours, reflecting strong momentum near its pivot point of $58. The stock shows bullish technical signals with moving averages supporting an uptrend. Fundamentally, CTSH maintains solid profitability with a 10.26% net margin and a modest P/E of 12.88. Recent earnings beats in Q4 2025 and Q1 2026 were offset by a Q2 2026 miss, with Q3 2026 results pending. Positive news includes AI-driven partnerships and employer awards, enhancing its growth narrative.
CTSH presents a balanced investment case with a consensus price target of $64.25 offering ~7% upside. Strengths include stable cash flow and undervaluation relative to peers, but risks involve IT spending pressures from AI disruption and competitive threats. Analyst sentiment is evenly split between Buy and Hold, indicating cautious optimism. The stock's outlook hinges on execution in AI services and sustaining margin discipline amid industry headwinds.
RVTY trades at $152.16, down 0.94% today, near its recent 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a Zacks upgrade to Buy (2026-10-02) and the launch of a new Type 1 diabetes screening kit in Europe (Business Wire, 2026-09-24).
The outlook is positive, supported by earnings momentum and strategic expansions, but the stock's premium valuation (P/E of 73.15) and margin pressures pose risks. Analyst consensus is bullish with a $132.13 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
